Tokyo Tape
Sign in
← Nipro

Quarterly report · Q3

8086.TEDINET S100Q5DE
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥406.3bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥494.8bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥369.4bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥13.2bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥19.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥13.8bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥27.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥20.6bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥14.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥19.1bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥7.0bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥11.0bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥8.1bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥12.2bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.05Tat 2022-12-31Cons.Assets
Total assets¥930.3bnat 2022-03-31Cons.Assets
Total assets¥902.8bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥809.0bnat 2022-12-31Cons.Liabilities
Total liabilities¥730.5bnat 2022-03-31Cons.Liabilities
Net assets / equity¥240.2bnat 2022-12-31Cons.Net assets
Net assets / equity¥199.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥193.7bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥102.7bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥95.3bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥42.692022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.352022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.682021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥22.92021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥37.822022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥64.772021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio21.3%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥3.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥530m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥2.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31¥166m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥28.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥28.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥22.5bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥318.8bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥314.2bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4.6bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥30.8bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥70.3bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥53.6bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥16.8bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.2bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-12-31¥42.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-12-31¥38.0bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.5bn
—segment totalrevenue2022-04-01 → 2022-12-31¥431.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥405.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥25.9bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥35.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥434.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥406.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥28.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥35.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥446m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥1.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31¥258m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥26.6bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥26.6bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥20.2bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue2021-04-01 → 2021-12-31¥284.8bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2021-04-01 → 2021-12-31¥280.0bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥4.8bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2021-04-01 → 2021-12-31¥31.0bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue2021-04-01 → 2021-12-31¥70.1bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue external2021-04-01 → 2021-12-31¥54.4bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥15.7bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentsegment profit2021-04-01 → 2021-12-31¥6.1bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue2021-04-01 → 2021-12-31¥39.1bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue external2021-04-01 → 2021-12-31¥34.5bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥4.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentsegment profit2021-04-01 → 2021-12-31¥2.5bn
—segment totalrevenue2021-04-01 → 2021-12-31¥394.1bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥368.9bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥25.1bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥39.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥396.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥369.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥26.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥39.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 449
ItemContextValueUnit
Provision for loss on disaster clCurrentQuarterInstant81000000JPY
Notes payable facilitiesPrior1YearInstant5882000000JPY
Notes payable facilitiesCurrentQuarterInstant3371000000JPY
Other clPrior1YearInstant37738000000JPY
Other clCurrentQuarterInstant33056000000JPY
Current liabilitiesPrior1YearInstant311993000000JPY
Current liabilitiesCurrentQuarterInstant332624000000JPY
Bonds payablePrior1YearInstant78700000000JPY
Bonds payableCurrentQuarterInstant77700000000JPY
Convertible bond type bonds with subscription rights to sharesPrior1YearInstant30270000000JPY
Convertible bond type bonds with subscription rights to sharesCurrentQuarterInstant30225000000JPY
Long term loans payablePrior1YearInstant267614000000JPY
Long term loans payableCurrentQuarterInstant316089000000JPY
Lease obligations nclPrior1YearInstant25626000000JPY
Lease obligations nclCurrentQuarterInstant25220000000JPY
Deferred tax liabilitiesPrior1YearInstant617000000JPY
Deferred tax liabilitiesCurrentQuarterInstant1212000000JPY
Net defined benefit liabilityPrior1YearInstant5927000000JPY
Net defined benefit liabilityCurrentQuarterInstant6044000000JPY
Provision for directors retirement benefitsPrior1YearInstant697000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant666000000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant11000000JPY
Provision for share based remuneration for directors and other officers nclCurrentQuarterInstant33000000JPY
Provision for loss on litigation nclPrior1YearInstant102000000JPY
Provision for loss on litigation nclCurrentQuarterInstant146000000JPY
Other nclPrior1YearInstant8893000000JPY
Other nclCurrentQuarterInstant19085000000JPY
Noncurrent liabilitiesPrior1YearInstant418460000000JPY
Noncurrent liabilitiesCurrentQuarterInstant476423000000JPY
LiabilitiesPrior1YearInstant730453000000JPY
LiabilitiesCurrentQuarterInstant809047000000JPY
Capital stockPrior1YearInstant84397000000JPY
Capital stockCurrentQuarterInstant84397000000JPY
Retained earningsPrior1YearInstant94667000000JPY
Retained earningsCurrentQuarterInstant96835000000JPY
Treasury stockPrior1YearInstant-10748000000JPY
Treasury stockCurrentQuarterInstant-10748000000JPY
Shareholders equityPrior1YearInstant168316000000JPY
Shareholders equityCurrentQuarterInstant170484000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant9789000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant6931000000JPY
Deferred gains or losses on hedgesPrior1YearInstant-108000000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-69000000JPY
Foreign currency translation adjustmentPrior1YearInstant6885000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant44914000000JPY
Remeasurements of defined benefit plansPrior1YearInstant356000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant738000000JPY
Valuation and translation adjustmentsPrior1YearInstant16922000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant52514000000JPY
Non controlling interestsPrior1YearInstant14628000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass